Soluble Epoxide Hydrolase Inhibition Improves Alzheimer's Disease Hallmarks: Correlation with Peripheral Inflammation and Gut Microbiota Modulation.

IF 6.9 2区 医学 Q1 GERIATRICS & GERONTOLOGY
Júlia Jarne-Ferrer, Christian Griñán-Ferré, Beatrice Jora, Sandra Codony, Lluïsa Miró, Cristina Rosell-Cardona, David Miñana-Galbis, Anna Pérez-Bosque, Santiago Vazquez, Mercè Pallàs
{"title":"Soluble Epoxide Hydrolase Inhibition Improves Alzheimer's Disease Hallmarks: Correlation with Peripheral Inflammation and Gut Microbiota Modulation.","authors":"Júlia Jarne-Ferrer, Christian Griñán-Ferré, Beatrice Jora, Sandra Codony, Lluïsa Miró, Cristina Rosell-Cardona, David Miñana-Galbis, Anna Pérez-Bosque, Santiago Vazquez, Mercè Pallàs","doi":"10.14336/AD.2025.0201","DOIUrl":null,"url":null,"abstract":"<p><p>Targeting brain inflammation has been proposed as a promising therapeutic strategy to cope with neurodegenerative diseases. Interestingly, accumulating data suggest that the gut microbiota partially exerts its neurodegenerative effects by exacerbating neuroinflammation through increased pathogenic or unhealthy genera that releases different types of cytokines in the periphery. Recently, soluble epoxide hydrolase enzyme (sEH) emerged as a new pharmacological approach for treating Alzheimer's Disease. Treatment with a sEH inhibitor (UB-BJ-02) modified the gut microbiota in the 5xFAD mouse model, increasing health-promoting genera such as Lactobacillus and Limosilactobacillus. By contrast, pro-inflammatory genera (e.g., Bacteroides) were decreased. UB-BJ-02 treatment enhanced the production of anti-inflammatory peripheral mediators in the colon and spleen, such as Il-10. 5xFAD mice treated with UB-BJ-02 showed improved short- and long-term memory and spatial memory compared to 5xFAD control. Furthermore, we found a reduction in neuroinflammatory markers evaluated by immunohistochemical assays, such as GFAP and IBA-1, and gene expression, such as Il-1β, Tnf-a, Il-6, and Trem2, in the brain of 5xFAD-treated mice and a significant decrease in the number of Aβ plaques. T Treatment decreased DRP1 protein levels while increasing OPA1 levels, resulting in improved mitochondrial function corroborated by the elevation of Pgc1-α. Interestingly, a correlation between UB-BJ-02 brain effects and microbiota changes were demonstrated. To validate this correlation, we fed CL4176 AD transgenic strain, with Limosilactobacillus reuteri and Bacteroides rodentium. Consequently, we observed that changes in feeding modified the number of Aβ plaques and neuroinflammatory markers in C. elegans. Therefore, the present study suggested that sEH inhibition with UB-BJ-02 promoted neuroprotective effects, modulating gut microbiota and modifying peripheral and brain pro-inflammatory markers.</p>","PeriodicalId":7434,"journal":{"name":"Aging and Disease","volume":" ","pages":""},"PeriodicalIF":6.9000,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Aging and Disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.14336/AD.2025.0201","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GERIATRICS & GERONTOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Targeting brain inflammation has been proposed as a promising therapeutic strategy to cope with neurodegenerative diseases. Interestingly, accumulating data suggest that the gut microbiota partially exerts its neurodegenerative effects by exacerbating neuroinflammation through increased pathogenic or unhealthy genera that releases different types of cytokines in the periphery. Recently, soluble epoxide hydrolase enzyme (sEH) emerged as a new pharmacological approach for treating Alzheimer's Disease. Treatment with a sEH inhibitor (UB-BJ-02) modified the gut microbiota in the 5xFAD mouse model, increasing health-promoting genera such as Lactobacillus and Limosilactobacillus. By contrast, pro-inflammatory genera (e.g., Bacteroides) were decreased. UB-BJ-02 treatment enhanced the production of anti-inflammatory peripheral mediators in the colon and spleen, such as Il-10. 5xFAD mice treated with UB-BJ-02 showed improved short- and long-term memory and spatial memory compared to 5xFAD control. Furthermore, we found a reduction in neuroinflammatory markers evaluated by immunohistochemical assays, such as GFAP and IBA-1, and gene expression, such as Il-1β, Tnf-a, Il-6, and Trem2, in the brain of 5xFAD-treated mice and a significant decrease in the number of Aβ plaques. T Treatment decreased DRP1 protein levels while increasing OPA1 levels, resulting in improved mitochondrial function corroborated by the elevation of Pgc1-α. Interestingly, a correlation between UB-BJ-02 brain effects and microbiota changes were demonstrated. To validate this correlation, we fed CL4176 AD transgenic strain, with Limosilactobacillus reuteri and Bacteroides rodentium. Consequently, we observed that changes in feeding modified the number of Aβ plaques and neuroinflammatory markers in C. elegans. Therefore, the present study suggested that sEH inhibition with UB-BJ-02 promoted neuroprotective effects, modulating gut microbiota and modifying peripheral and brain pro-inflammatory markers.

可溶性环氧化物水解酶抑制改善阿尔茨海默病特征:与外周炎症和肠道微生物群调节相关。
靶向脑炎症已被提出作为一种有前途的治疗策略来应对神经退行性疾病。有趣的是,越来越多的数据表明,肠道微生物群通过增加致病或不健康的属,在周围释放不同类型的细胞因子,从而加剧神经炎症,从而部分地发挥其神经退行性作用。近年来,可溶性环氧化物水解酶(sEH)成为治疗阿尔茨海默病的一种新的药理途径。sEH抑制剂(UB-BJ-02)修饰了5xFAD小鼠模型中的肠道微生物群,增加了促进健康的属,如乳酸杆菌和乳酸杆菌。相比之下,促炎属(如拟杆菌)减少。UB-BJ-02治疗可增强结肠和脾脏中抗炎外周介质如Il-10的产生。与5xFAD对照组相比,用UB-BJ-02治疗的5xFAD小鼠的短期、长期记忆和空间记忆均有所改善。此外,我们发现5xfad处理的小鼠大脑中神经炎症标志物(如GFAP和IBA-1)和基因表达(如Il-1β、Tnf-a、Il-6和Trem2)减少,a β斑块数量显著减少。T治疗降低DRP1蛋白水平,同时增加OPA1蛋白水平,导致线粒体功能改善,Pgc1-α升高证实了这一点。有趣的是,UB-BJ-02对大脑的影响与微生物群的变化之间存在相关性。为了验证这一相关性,我们饲养了CL4176 AD转基因菌株,其中含有罗伊氏乳杆菌和拟杆菌。因此,我们观察到喂养的变化改变了秀丽隐杆线虫的Aβ斑块和神经炎症标志物的数量。因此,本研究表明,UB-BJ-02抑制sEH可促进神经保护作用,调节肠道微生物群,改变外周和脑促炎标志物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Aging and Disease
Aging and Disease GERIATRICS & GERONTOLOGY-
CiteScore
14.60
自引率
2.70%
发文量
138
审稿时长
10 weeks
期刊介绍: Aging & Disease (A&D) is an open-access online journal dedicated to publishing groundbreaking research on the biology of aging, the pathophysiology of age-related diseases, and innovative therapies for conditions affecting the elderly. The scope encompasses various diseases such as Stroke, Alzheimer's disease, Parkinson’s disease, Epilepsy, Dementia, Depression, Cardiovascular Disease, Cancer, Arthritis, Cataract, Osteoporosis, Diabetes, and Hypertension. The journal welcomes studies involving animal models as well as human tissues or cells.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信